Compared with IL-15+biNV, biNV-IL-15 manifested dramatically enhanced anticancer activity and prolonged survival for over 49 days, which is likely due to its targeted delivery and local retention in secondary lymphatic organ, and spatiotemporally synchronous delivery of IL-15 and tumor antigen through biNV-IL-15 for enhanced tumor-specific T cell activation. Here, IL15 is linked to neoplasm.